These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 21871775

  • 1. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.
    Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S.
    Can J Cardiol; 2011; 27(5):548-54. PubMed ID: 21871775
    [Abstract] [Full Text] [Related]

  • 2. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH, Hao QQ, Jia XW, Fan WZ, Gu XS, Wu WL, Hao GZ, Li SQ, Jiang YF, Geng W.
    Chin Med J (Engl); 2008 Mar 20; 121(6):522-7. PubMed ID: 18364139
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS, Ottervanger JP, ten Berg JM, Gosselink AT, van Houwelingen G, Dambrink JH, Stella PR, Hamm C, van 't Hof AW, On-TIME 2 Trial Investigators.
    J Invasive Cardiol; 2012 Mar 20; 24(3):84-9. PubMed ID: 22388296
    [Abstract] [Full Text] [Related]

  • 5. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
    Xia JG, Qu Y, Shen H, Liu XH.
    Coron Artery Dis; 2013 Sep 20; 24(6):522-6. PubMed ID: 23900046
    [Abstract] [Full Text] [Related]

  • 6. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EM, Braunwald E, Wiviott SD.
    J Am Coll Cardiol; 2014 Jan 28; 63(3):225-32. PubMed ID: 24140678
    [Abstract] [Full Text] [Related]

  • 7. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS, van Werkum JW, Ottervanger JP, Breet NJ, Gosselink AT, van Houwelingen KG, Dambrink JH, Hamm C, ten Berg JM, van 't Hof AW, Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group.
    Catheter Cardiovasc Interv; 2012 May 01; 79(6):956-64. PubMed ID: 22162050
    [Abstract] [Full Text] [Related]

  • 8. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald E, TIMI Study Group.
    Am Heart J; 2008 Jan 01; 155(1):133-9. PubMed ID: 18082504
    [Abstract] [Full Text] [Related]

  • 9. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R, Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators.
    Circulation; 2009 Jun 30; 119(25):3215-22. PubMed ID: 19528337
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Kırma C, Erkol A, Pala S, Oduncu V, Dündar C, İzgi A, Tigen K, Gibson CM.
    Catheter Cardiovasc Interv; 2012 Jan 01; 79(1):59-67. PubMed ID: 21523892
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD.
    J Am Coll Cardiol; 2009 Aug 18; 54(8):678-85. PubMed ID: 19679245
    [Abstract] [Full Text] [Related]

  • 15. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT, Kurz K, Keck F, Staritz P, Lehrke S, Katus HA, Giannitsis E.
    Thromb Haemost; 2008 Oct 18; 100(4):648-54. PubMed ID: 18841288
    [Abstract] [Full Text] [Related]

  • 16. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study.
    Patti G, Bárczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, Barbato E, Merkely B, Edes I, Ostojic M, Wijns W, Di Sciascio G.
    J Am Coll Cardiol; 2011 Oct 04; 58(15):1592-9. PubMed ID: 21958886
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
    Kralisz P, Dobrzycki S, Nowak K, Kochman W, Gajewska-Bachórzewska H, Gugała K, Mezyński G, Prokopczuk P, Zuk J, Korecki J, Poniatowski B, Musiał W.
    Kardiol Pol; 2004 May 04; 60(5):459-67. PubMed ID: 15247961
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G, Marin-Neto JA, Parsons LS, Canto JG, Rogers WJ, National Registry of Myocardial Infarction-4.
    Am J Cardiol; 2006 Nov 01; 98(9):1125-31. PubMed ID: 17056312
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.